Sleeping Bruxism Treatment Market – A market with high CAGR and return on investment by 2023

 The latest report by Market Research Future (MRFR) affirms that the global sleeping bruxism treatment market is set to accrue USD 638.22 million at 6.7% CAGR during the forecast period (2018–2023). This growth can be put down to growing prevalence of dental diseases and consequently growing dental procedures coupled with growing funding and healthcare insurance coverage across the globe. Moreover, changing lifestyle, elevating demand for affordable healthcare delivery systems, rapid health insurance penetration, mergers and acquisitions to reach untapped markets, and government initiatives trigger the global market growth. Also, aging population and stressful lives led by a large population have an influence on the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5422

However, restraining factor such as expensive treatment may hinder the market growth to some level. On the flip side, several types of research and tests are being conducted to enhance treatment for sleep bruxism. Various methods such as drug therapy, behavioral therapy, custom dental and mouth guards are being developed to find out the most effective treatment procedure for sleeping bruxism. These researches help upgrade the treatment procedures, thus leading to market growth.

One of the most popular trends creating waves in sleeping bruxism treatment market is treating patient with behavior therapy. It involves the patient practicing proper jaw and mouth positions. The patient can also rest the tongue up with teeth apart and closed lips, which will counteract grinding.

Global Market for sleeping bruxism treatment – Segmental Analysis

MRFR’s report states that the sleeping bruxism treatment market is segmented on the basis of type, diagnosis, treatment type, cause, patient type, and end-user.

By type, the market is segmented into primary bruxism and secondary bruxism. The secondary bruxism segment accounted for the largest market share in 2017. Increasing sleep disorders, growing consumption of medicines which lead to dental side effects, and changing lifestyle due to stress can fuel the growth of the secondary bruxism segment.

By treatment, the market is segmented on the basis of dental approaches and medication. The dental approaches segment is divided into mouth guard and NTI-tss device. The medication segment is sub-segmented on the basis of muscle relaxants, Botox injections, and anti-anxiety drugs.

By cause, the global sleeping bruxism treatment market is segmented on the basis of obstructive sleep apnea, sleep paralysis, gastroesophageal reflux disease (GERD), malocclusion, and others. Among these, the obstructive sleep apnea segment is estimated to be worth USD 233.20 million by 2023, growing at a CAGR of 7.0% during the forecast period.

Pediatric and adult are two major segments under patient type. The pediatric segment held the largest market share in 2017. Prevalence of hyperactivity among children, growing anger issues, increasing pain from earache and teething, and even growing stress has fueled the growth of pediatric segment.

The end-users in the global sleeping bruxism treatment market are hospitals, dental clinics, and others. The end-users in the market are growing rapidly and will continue to grow at the same pace throughout the forecast period. The number of dental clinics has increased owing to growing awareness among patients regarding bruxism, government funding, and increasing number of dentists opening up standalone clinics.

Regional Outlook

The Americas market accounted for 39.1% share in 2017 in the sleeping bruxism treatment market. Factors such as rising stress and anxiety among the population have led to this market growth. Rising government funding and growing healthcare insurance coverage also contribute to the market’s expansion in the region.

Europe is the second largest market owing to growing cases of sleeping bruxism. High economy, growing dental awareness, growing number of dental clinics and healthcare infrastructure aid in market growth in the region. A large number of people also suffer from sleep disorders, snoring and irregular breathing which gives rise to sleeping bruxism, driving the market progress in the area.

On the other hand, Asia Pacific will observe steady growth due to rapid adoption of sophisticated healthcare technology, rapid economic growth, massive population size, and rise in investments in the healthcare sector. The pediatric population is growing tremendously which also shapes the market size positively. Furthermore, elevating awareness in terms of sleep bruxism and rapidly growing dental industry in countries such as China, India, Japan, and South Korea can spur overall market demand.

The Middle East & Africa market will experience sluggish growth as there is less exposure to the healthcare services along with lack of awareness about sleeping bruxism.

Global market for sleeping bruxism treatment– Competitive Dashboard

The key players competing in the market are S4S Dental Laboratory, Ipsen Biopharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Ivoclar Vivadent AG, Randmark and Dental Products LLC.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/sleeping-bruxism-treatment-market-5422 

Allergy Immunotherapy Market is expected to rise at a remarkable CAGR By 2023

 The Global Allergy Immunotherapy Market is expected to register 10.85% CAGR and reach USD 4,324.7 million by 2023. Allergy immunotherapy is a disease-adapting therapy that is effective for the treatment of allergic rhinitis/conjunctivitis, allergic asthma, peanuts allergy, cat allergy, and stinging insect hypersensitivity. This involves the regular administration of gradually increasing the dose of allergen extracts into the patient’s body over a certain period.

The launch of new sublingual immunotherapies in emerging economies and the presence of major players in allergen immunotherapy market is expected to drive the market during the forecast period. However, the restricted healthcare spending in the underserved market of Europe will restrain the growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1517

According to a recent study published by the Market Research Future analysts, the global allergy immunotherapy market is growing at a double digit growth rate; mainly due to launch of the new sublingual immunotherapies in emerging economies, introduction of several allergen immunotherapy tablets (AITs) by major players, increase in risk factors causing allergies, rise in the screening rate for allergies, and current reimbursement scenario.

On the other hand, the allergy sector is unfortunately underrated and neglected in the context of global medical sector. According to the reports, Europe, being the largest market for allergy immunotherapy has 150 million patients suffering from chronic allergic diseases. Out of this patient population, half of them are underdiagnosed or poorly managed due to a lack of awareness and shortage of medical specialists. That being said, this scenario is changing with time. There has been an increase in screening for allergens due to rising income, government initiatives for screening, increasing penetration of diagnostic and healthcare etc. Availability of easy diagnostic kits for testing allergies and the serious nature of allergic reactions has led to the growth of market. Allergic reaction are a medical emergency. The reimbursement for medical emergencies is higher due to their high life threatening nature which is expected to drive the future market for allergy immunotherapy. 

Global Allergy Immunotherapy Market - Competitive Analysis

There are large number of companies involved in the development of the drugs and therapies for the allergy which are now being used in majority part of the developed countries. Global market for allergy immunotherapy is majorly dominated by six companies namely ALK-Abelló A/S, Stallergenes Greer, HAL Allergy Group, Allergy Therapeutics, Merck Group, and others. ALK-Abello taking about 38%, and Stallergenes Greer capturing 23%, these two companies hold more than half the global market for allergy immunotherapy.

ALK-Abelló A/S offers allergy immunotherapy products in the form of injections, sublingual drops and sublingual tablets. In January 2017, the company has acquired the operating assets in Allergy Laboratory of Oklahoma Inc., and Crystal Labs LLC. Back in 2015, the company took over the allergy immunotherapy activities of its former distributor in Turkey, Albio Allerji Ürünleri Ith. Ve Tic. Ltd. Sti. (Albio).

Another big player, Stallergenes Greer was form in 2015 by the union of two companies Stallergenes, and Greer. The company has adapted strategy of mergers and acquisitions for its growth in the allergy immunotherapy market. It provides both sublingual and subcutaneous immunotherapies. Besides that, HAL Allergy is one of the leading companies in the field of allergen immunotherapy (AIT).

Apart from these major companies, there are players like Sementis, Biomay AG, Adamis Pharmaceuticals Corporation, DBV Technologies, Circassia, and others which manufactures particular types of subcutaneous and sublingual immunotherapy majorly operate in specific regions and countries.

The global market consist of players such as ALK Abello A/S (Denmark), Allergy Therapeutics (UK), Circassia (UK), DBV Technologies (France), Stallergenes Greer (UK), Merck KGaA (Allergopharma) (Germany), and HAL Allergy Group (Netherlands)  are some of the prominent players at the forefront of competition in the global allergy immunotherapy market and are profiled in MRFR Analysis report.  

Global Allergy Immunotherapy Market - Regional Analysis

Europe is holding the largest market share in global immunotherapy market. The biggest factor in this large share is the huge patient population for the different types of allergies. Some major factors that attribute the growth of Europe immunotherapy market are, rise in prevalence of chronic diseases like allergy, asthma, diabetes and hypertension.

Americas is the second largest region in the allergy immunotherapy market. The growth in the American market is majorly due to the rise in the patient population and the number of product launches in recent years. To increase their share in the market companies are introducing more and more allergen immunotherapy tablets (AITs) in potential markets. For instance, products such as Mitizax (HDM) tablets, Merck’s Grastek (grass), Ragwitek (ragweed), and Greer’s Oralair (grass) were launched in the U.S. in between 2014-2015.

Asia Pacific region is far behind the major two regions in terms of value. Some of the reasons include non-existence of Japanese market for allergy immunotherapy, despite having a large population with allergic rhinitis, fewer than 6,000 patients were treated with Specific Immunotherapy in 2013.

Middle East & Africa current;y contributes least in the global market. However, there has been increase in the spending for healthcare in this region. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily in recent years. Because of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is about 80% to 90%.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market  

Growth Hormone Market is expected to rise at a remarkable CAGR By 2023

 Market Research Future (MRFR’s) latest study reveals that the global market for human growth hormone will surge at an impressive CAGR of 7.50% during the review period (2018-2023). Growth hormone deficiency falls under the list of endocrine conditions. Growth hormone deficiency is prevalent across the globe and the reasons for the condition usually vary from person to person. Though the condition is rare, its prevalence rate has increased to a noteworthy level in recent times. In many cases, brain injury has been identified as a primary cause of growth hormones deficiency. Low level of growth hormone secretion can lead to altered body composition, osteoporosis, insulin resistance, lipid abnormalities, reduced energy levels, and reduced muscle strength. Low growth hormone secretion is usually an issue that starts at a young age and if not addressed promptly, may have major implications in later stages of life.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6494 

Today, the level of awareness about the condition is much higher than in the past. Modern parents show higher vigilance in monitoring their offspring’s overall physical development and are quick to react to any anomaly they observe. Increasing awareness about endocrine disorders is reflecting favourably on the global human growth hormone market. Demand for growth hormones has increased substantially. Moreover, arrival of more effective hormones has had a positive impact on the popularity of such medical products.

Global Human Growth Hormone Market: Segmental Analysis

MRFR’s report offers a thorough segmental analysis of the market on the basis of brand, route of administration, application, and distribution channel. By brand, the market has been segmented into norditropin, genotropin, mumatrope, sainzen, omnitrope and others. Among these, the norditropin segment is holds the dominant share of the market and is expected retain its positing over 2023. In 2017, the segment stood at USD 1494.98 Mn and is projected to witness a double-digit CAGR during the forecast period. By application, the market has been segmented into growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome,

prader-willi syndrome and others. The growth hormone deficiency segment accounts for the largest share of the market and is expected to exhibit a CAGR of 7.07% during the assessment period. By route of administration, the market has been segmented into subcutaneous, intramuscular, intravenous and oral. The subcutaneous segment currently holds the leading position and accounted for more than two-third share of the market in 2017. The segment is expected to remain highly attractive throughout the assessment period. By distribution channel, the market is segmented into hospital pharmacies, clinics, retail pharmacies and e-commerce websites. The hospital pharmacies segment represented close to 40% market share in 2017 and is project to witness a health growth over the next couple of years.

Global Human Growth Hormone Market: Regional Analysis

The report covers the human growth hormone market across Americas, Asia Pacific (APAC), Europe, the Middle East & Africa. The market is Americas is expected to remain highly lucrative during the review period. In 2017, Americas commanded over 49.18% share of the market and is expected to maintain its dominant position in 2018 and beyond. Factors such as the increasing prevalence of growth hormone deficiency, high healthcare spending, and widespread awareness among consumers are partly driving the growth of the market in the region. Americas is followed by Europe and APAC respectively. Sales of human growth hormones have also picked up pace in GCC countries, which brings MEA under the radar of market players operating on a global level.

Global Human Growth Hormone Market: Competitive Landscape

Some of leading market players profiled in the report include Pfizer Inc., Novo Nordisk A/S, Anhui Anke Biotechnology Co. Ltd., Eli Lilly and Company, GeneScience Pharmaceuticals Co. Ltd., Genetech Inc., Novartis AG, Biopartners GmbH, Zhongshan Hygene Biopharm Co. Ltd., Merck KGaA, Ipsen S.A. and Lifetech Labs

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/human-growth-hormone-market-6494  

Myelodysplastic Syndrome (MDS) Drugs Market: Information, Analytical Insights and growth of 2020 – 2025

 Market Highlights

The Global Myelodysplastic Syndrome (MDS) drugs market is expected to grow significantly over the forecast period. The Myelodysplastic Syndrome (MDS) drugs market held a valuation of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.

The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved generic injectable product decitabine for Lupin Ltd. There are various other MDS medications available in the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8134 

Various other factors that are driving the MDS drugs market are the promotion of clinical studies related to MDS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufactures.

However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.

Segmentation

The global Myelodysplastic Syndrome (MDS) drugs market is segmented based on product, type of syndrome, route of administration, end user, and region.

Based on product, the global Myelodysplastic Syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.

The MDS drugs market at a global level is segmented on type of syndrome into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.

Based on the route of administration, the market is segmented into oral, parenteral, and others. The MDS drugs available in the market are administered through parenteral route, for instance, intravenous or subcutaneous. The parental route has a quick effective after administration. Thus, the parenteral segments have greater growth compared to the other dosage forms in this segment. Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. MDS patients are treated in the hospitals, clinics, and ambulatory surgical centers. MDS drugs are prescribed by physicians to patients, as in critical conditions, it could lead to blood cancer. The hospitals segment holds the major share in this segment as it deals with a larger number of MDS patients compared to clinics and ambulatory surgical centers.

Key Players

Various players operate in the global Myelodysplastic Syndrome (MDS) Drugs market such as BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr. Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries Inc, and others.

Regional Analysis

In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The global MDS drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European global MDS drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The MDS drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The global Myelodysplastic Syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/myelodysplastic-syndrome-drugs-market-8134 

Dental Restorative and Regenerative Material Market Foreseen to Draw a Promising Growth by 2023

 The Global Dental Restorative and the Regenerative Material Market are expected to register a CAGR of 6.7% and is anticipated to reach USD 2679.7 Million by 2023. 

Dental restorative and regenerative materials are used to replace damaged or lost teeth, mostly it happens due to dental caries or dental cavities. Simultaneously, dental restorative and regenerative materials are also used in cosmetic dentistry, which improves the appearance of the teeth and enhances the smile of an individual.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/4332  

The increasing prevalence of dental disorders, availability of identical material, growing dental tourism, rising adherence and biocompatibility, and increasing disposable income are responsible for propelling the market growth. However, the high cost of dental restorative and regenerative material and lack of awareness about dental procedures are hampering the growth of the market.

Market Dynamics

The rise in the cases of dental complications is expected to drive the growth of the market. According to the World Dental Federation, more than 3.9 billion people are affected by oral diseases, and about half of the world’s population is suffering from untreated tooth decay. Moreover, increasing dental tourism is also likely to support market growth. On the other hand, the high cost of dental materials and lack of awareness is anticipated to hamper the market growth.

Segmentation

The global dental restorative and the regenerative material market has been segmented into type and end user. By type, the market has been segmented into restorative material and regenerative material. Restorative material segment has been divided into an amalgam, resin-base composite, glass ionomer, resin-modified glass ionomer, porcelain, metal, porcelain-fused-to-metal. The regenerative material segment is further segmented into bone graft materials, membranes, and tissue regeneration products.  

Based on end user, the market has been segmented into dental research laboratories and dental hospitals and clinics. The dental hospitals and clinics segment accounted for a market share of 82.30% in 2016.

Key Players

The prominent players in the global dental restorative and regenerative material market are DENTSPLY Sirona, Henry Schein, Inc., Kerr Corporation, Keystone Dental, Inc., Nobel Biocare Services AG, 3M, Biotech Dental, botiss biomaterials GmbH, Institut Straumann AG, and Zimmer Biomet.

Some of the key strategies followed by the players operating in the global dental restorative and regenerative material market were innovation, product development, acquisition, and expansion.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/dental-regenerative-material-market-4332

Global AR & VR in Healthcare Market is Expected to Experience Immense Growth During 2020 – 2023

 

Market Highlights

The AR & VR in healthcare market is expected to grow at an approximate CAGR of 30.2% during forecast period, 2018–2023.

Rising demand to reduce healthcare cost is one of the key factors driving the AR & VR in healthcare market. For instance, with the use of AR navigation system nearly USD 288 million can be saved on minimally-invasive surgical procedures in the US.

Various other factors such as rising government funding, high prevalence of chronic diseases, rising adoption of AR and VR in fitness management, increasing penetration of connected devices in the healthcare sector, and rising awareness about VR therapy are also expected to propel the growth of the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7208 

However, concerns regarding data privacy, lack of expertise among medical practitioners, and lack of competence in deployment of the AR and VR solutions can hinder the market growth over the forecast period.

Segmentation

The AR & VR in healthcare market is segmented based on technology, offering, device type, application, end user, and region.

The global market for AR & VR in healthcare, by technology is segmented into AR technology and VR technology. The AR technology segment is further classified as marker-based AR and markerless AR. The marker-based AR segment includes passive marker, and active marker. The markerless AR segment includes model-based tracking, and image processing-based tracking. The VR technology segment is further classified as nonimmersive technology, and semi-immersive and fully immersive technologies.

Based on offering, the market is segmented into hardware components and software. The hardware components segment is further classified as sensors, semiconductor component, displays and projectors, position tracker, cameras, and others. The sensors segment includes accelerometer, gyroscope, magnetometer, and proximity sensor. The semiconductor component segment includes controller/processor, and integrated circuits. The software segment is further classified as software development kits, and cloud-based services.

Based on device type, the market is segmented into AR device type, and VR device type. The AR device type segment is further classified as head-mounted display, and handheld device. The VR device type segment is further classified as head-mounted display, gesture-tracking device, and projectors and display walls. The gesture-tracking device segment includes data gloves, and others.

Based on application, the market is segmented into fitness management, patient care management, surgery, pharmacy management, medical training and education, and others.

Based on end user, the market is segmented into hospitals & clinics, surgical centres, pharmaceutical companies, research and academic institutes, and others.

Regional Analysis

The Americas dominated the global market for AR & VR in healthcare owing to the rising demand to reduce healthcare cost and presence of major market players.

In 2017, it was estimated that Europe stood second in the AR & VR in healthcare market. This can be attributed to the rising funding for innovation and increasing technological advancements. For instance, the European Union’s Horizon 2020 programme is allocating nearly USD 91.51 billion of funding over seven years for research and innovation.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and high prevalence of chronic diseases drives the regional markets of the Asia Pacific region.

On the other hand, the Middle East and Africa held least share in the AR & VR in healthcare market due to the low per capita income and stringent government policies, especially within the African region.

Key Players

Some of the key players in the AR & VR in healthcare market are Atheer, Augmedix, Daqri, Firsthand Technology, Google, Medical Realities, Microsoft, Mindmaze, Oculus VR, Psious, EchoPixel, Inc., Osso VR Inc., SURGICAL THEATER, LLC, Orca Health, Inc., Hologic Inc., 3D Systems, Inc., and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/ar-vr-in-healthcare-market-7208  

Theranostics Market – A market with high CAGR and return on investment by 2025

 Market Highlights

The global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period. Theranostics is a new field of medicine which combines therapeutics, nanoscience, and diagnostics based on specific targeted diagnostic tests. Theranostics is also called as theragnostics or companion diagnostics (CDx), or pharmacodiagnostics or personalized medical care, or personalized therapy, or personalized medicine technology. Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment. Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases. In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8057 

Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules. Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.

Segmentation

The global theranostics market has been segmented into the therapeutic area, technology, end user, and region.

By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others. The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.

On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others. The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.

Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.

Key Players

Few of the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc.

Regional Analysis

The global theranostics market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On a regional basis, the Americas would command the market throughout the forecast period attributed to the domicile of major market participants, increasing research and development activities, and growing adoption of theranostics in the US and Canada. For instance, in June 2018, Genome Canada launched a national initiative for clinical implementation of precision health that would ultimately impact the market growth in the near future.

Europe would follow Americas in terms of value over the forecast period due to flourishing pharmaceutical and medical device companies, increasing partnerships and collaborations between life science companies and medical diagnostics companies, and growing personalized medicine sector. Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment, and care which is assisting in addressing the challenge of the aging of the population, rising prevalence of chronic diseases, and increasing healthcare costs.

The market in Asia-Pacific would register the fastest market growth over next seven years owing to booming medical tourism, swiftly developing healthcare infrastructure, and growing awareness in the developing countries, namely, India, China, Singapore, and Australia.

The Middle East & Africa has the least share of the global theranostics market. In addition, the major market share of the region would be held by the Middle Eastern region due to developing healthcare system and medical infrastructure in the Arab countries.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/theranostics-market-8057